Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small-Cell Lung Cancer in China.
作者信息
Mu Lifeng, Zhou Benhong
机构信息
Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, People's Republic of China.
出版信息
Adv Ther. 2020 Feb;37(2):968-970. doi: 10.1007/s12325-019-01204-0. Epub 2020 Jan 4.
Abstract
摘要
相似文献
1
Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small-Cell Lung Cancer in China.
Adv Ther. 2020 Feb;37(2):968-970. doi: 10.1007/s12325-019-01204-0. Epub 2020 Jan 4.
2
Response Letter to "Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China".
Adv Ther. 2020 Feb;37(2):971-972. doi: 10.1007/s12325-019-01202-2. Epub 2020 Jan 4.
3
Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China.
Adv Ther. 2019 May;36(5):1114-1125. doi: 10.1007/s12325-019-00908-7. Epub 2019 Mar 21.
4
Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study.
Lancet Respir Med. 2019 May;7(5):437-446. doi: 10.1016/S2213-2600(19)30053-0. Epub 2019 Apr 10.
5
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
N Engl J Med. 2017 Aug 31;377(9):829-838. doi: 10.1056/NEJMoa1704795. Epub 2017 Jun 6.
6
The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib.
J Med Econ. 2017 Jul;20(7):671-677. doi: 10.1080/13696998.2017.1302453. Epub 2017 Mar 23.
7
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
Lancet. 2017 Jul 1;390(10089):29-39. doi: 10.1016/S0140-6736(17)30565-2. Epub 2017 May 10.
8
Alectinib Approved for ALK+ Lung Cancer.
Cancer Discov. 2016 Feb;6(2):115. doi: 10.1158/2159-8290.CD-NB2016-001. Epub 2016 Jan 6.
9
How Should We Treat Alectinib-Refractory ALK-Positive Non-Small Cell Lung Cancer?
J Thorac Oncol. 2018 Oct;13(10):1438-1440. doi: 10.1016/j.jtho.2018.07.009.
10
Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP.
J Clin Oncol. 2017 May 10;35(14):1515-1521. doi: 10.1200/JCO.2016.70.5749. Epub 2017 Mar 15.
本文引用的文献
1
Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China.
Adv Ther. 2019 May;36(5):1114-1125. doi: 10.1007/s12325-019-00908-7. Epub 2019 Mar 21.
2
The efficacy and safety of ALK inhibitors in the treatment of ALK-positive non-small cell lung cancer: A network meta-analysis.
Cancer Med. 2018 Oct;7(10):4993-5005. doi: 10.1002/cam4.1768. Epub 2018 Sep 19.
3
Extrapolation of Survival Curves from Cancer Trials Using External Information.
Med Decis Making. 2017 May;37(4):353-366. doi: 10.1177/0272989X16670604. Epub 2016 Sep 29.
4
Comprehensive decision analytical modelling in economic evaluation: a Bayesian approach.
Health Econ. 2004 Mar;13(3):203-26. doi: 10.1002/hec.804.
Zotero 插件